National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology

American Journal of Geriatric Psychiatry

Volumn 9, Issue 4, 2001, Pages 346-360

  Schneider, Lon S ^a,b   Tariot, Pierre N ^a   Lyketsos, Constantine G ^a   Dagerman, Karen S ^a   Davis, Kenneth L ^a   Davis, Sonia ^a   Hsiao, John K ^a   Jeste, Dilip V ^a   Katz, Ira R ^a   Olin, Jason T ^a   Pollock, Bruce G ^a   Rabins, Peter V ^a   Rosenheck, Robert A ^a   Small, Gary W ^a   Lebowitz, Barry ^a   Lieberman, Jeffery A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGITATION; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MENTAL HEALTH SERVICE; OUTPATIENT CARE; PATIENT COUNSELING; PSYCHOSIS; TREATMENT OUTCOME;

EID: 0034752199     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200111000-00004     Document Type: Article

References (43)

1. Treatment of the elderly suffering from psychosis and dementia
2. Efficacy of treatment for geropsychiatric patients with severe mental illness
3. Effects of antipsychotic withdrawal in elderly nursing home residents
4. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations
5. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer's disease
6. The course of psychopathologic features in mild-to-moderate Alzheimer disease
7. A meta-analysis of controlled trials of neuroleptic treatment in dementia
8. Psychosis of Alzheimer's disease and related dementias: Diagnostic criteria for a distinct syndrome
9. Conventional vs. newer antipsychotics in elderly patients
10. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
11. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
12. A family intervention to delay nursing home placement of patients with Alzheimer's disease: A random controlled trial
13. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia
14. Costs, effects, and C/E ratios alongside a clinical trial
15. Regression models and life tables
16. Categorical data analysis, in statistical methodology in the pharmaceutical sciences
17. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients
18. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
19. Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
20. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
21. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
22. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
23. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
24. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
25. Validity and reliability of the Alzheimer's Disease Cooperative Study Clinical Global Impression of Change
26. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia
27. The brief psychiatric rating scale
28. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease
29. Predicting time to nursing home care and death in individuals with Alzheimer's disease
30. Concepts and methods in the development of the ADRQL: An instrument for assessing health-related quality of life in persons with Alzheimer's disease
31. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician
32. Development of cognitive instruments for use in clinical trials of anti-dementia drugs
33. Interrater reliability issues in multicenter trials, part I: Theoretical concepts and operational procedures in VA Cooperative Study #394
34. A rating scale for drug-induced akathisia
35. The "General Medical Health Rating" (GMHR): A bedside global rating of medical comorbidity in patients with dementia
36. An inventory of measuring depression
37. Efficacy of interventions for caregivers: A reanalysis
38. The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer's disease